Month: September 2019

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical TrialGrowing Body of Evidence Supporting Use of the Tack Endovascular System®to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD

September 27, 2019 – WAYNE, Pa.–(BUSINESS WIRE)– Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive one-year results of its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial, successfully achieving both primary and secondary endpoints. Marianne Brodmann, M.D., Head of the Clinical Division of Angiology, Medical …

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical TrialGrowing Body of Evidence Supporting Use of the Tack Endovascular System®to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD Read More »

Intact Vascular to Announce One-Year Data from TOBA III Clinical TrialStudy Investigates Use of the Tack Endovascular System® for Focal Dissection Repair Following Drug-Coated Balloon Angioplasty in PAD Patients

September 16, 2019 – WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the one-year data from its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial will be presented during the High Impact Clinical Research session of the 31st Transcatheter Cardiovascular Therapeutics (TCT) meeting, the …

Intact Vascular to Announce One-Year Data from TOBA III Clinical TrialStudy Investigates Use of the Tack Endovascular System® for Focal Dissection Repair Following Drug-Coated Balloon Angioplasty in PAD Patients Read More »

Scroll to Top
Intact Vascular uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this.